GeneDx Holdings (WGS) stock price is $66.29, up 4.21% on the day, as of Oct 19, 2026. It has a market cap of $1.96Bn, and is classified in the Diagnostic Labs industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.96 Bn
P/E-18.43
P/S4.31
Div. Yield0.00
Total Debt (Qtr)96.84 Mn
Revenue Growth (1y) (Qtr)11.44
Add ratio to table…
About
GeneDx Holdings Corp. is a genomics company that focuses on delivering exome and genome sequencing services for the diagnosis of genetic disorders. The firm combines clinical laboratory expertise with a proprietary dataset called GeneDx Infinity to power its ExomeDx and GenomeDx tests which have received FDA Breakthrough Device Designation. Founded in 2000 by scientists from the National Institutes of Health the company built one of the world’s largest rare disease…
GeneDx Holdings Corp. is a genomics company that focuses on delivering exome and genome sequencing services for the diagnosis of genetic disorders. The firm combines clinical laboratory expertise with a proprietary dataset called GeneDx Infinity to power its ExomeDx and GenomeDx tests which have received FDA Breakthrough Device Designation. Founded in 2000 by scientists from the National Institutes of Health the company built one of the world’s largest rare disease repositories and continues to develop rapid ultra rapid genome sequencing protocols. GeneDx aims to shift genetic testing from reactive panel based approaches to comprehensive exome and genome analysis that can be used as a first tier test across pediatric outpatient neonatal intensive care and prenatal settings. The firm also seeks to expand its data and biopharma solutions business by leveraging its extensive genomic and phenotypic information to support drug discovery clinical trial recruitment and real world evidence generation. GeneDx Holdings Corp. operates CLIA certified high complexity laboratories in Gaithersburg Maryland and holds additional state licenses in New York California Pennsylvania and Rhode Island. The company’s mission emphasizes empowering patients to live their healthiest life through genomics while promoting equity simplicity and transparency in all its activities.
GeneDx Holdings Corp. generates revenue primarily from the sale of diagnostic test reports for exome and genome sequencing. The core offering includes ExomeDx GenomeDx and related rapid turnaround products that are billed to third party payors patients business to business clients and healthcare partners. In addition to test revenue the company earns income from data and information solutions that provide access to the GeneDx Infinity dataset variant interpretation pipelines and cloud based analysis services for biopharma and research organizations. Newborn screening products and associated information services represent an emerging revenue stream as the firm expands its genome based screening initiatives. The firm also receives modest revenue from international referral sources which currently account for about 1.5 percent of total sales. Revenue exhibits modest seasonal variation with higher volumes in the fourth quarter attributable to patients meeting annual insurance deductibles and lower volumes in the first quarter. Over time GeneDx expects to increase the proportion of revenue derived from data solutions newborn screening and information services while maintaining a strong foundation in diagnostic testing.
GeneDx Holdings Corp. holds a leading position in the genetic diagnostics industry due to the scale and diversity of its GeneDx Infinity dataset which contains over 2.5 million tests including more than one million exomes and genomes and a substantial proportion of non European ancestry samples. This extensive resource enables the firm to deliver high diagnostic yield and reduced uncertain results compared to competitors that rely on smaller or less diverse public databases. The company’s competitive advantages include a CLIA accredited high complexity laboratory a team of over one hundred medical doctors and PhDs and more than one hundred fifty genetic counselors who provide expert interpretation. GeneDx has integrated artificial intelligence tools such as the Multiscore gene ranker to accelerate variant analysis and improve turnaround time. The firm’s ExomeDx and GenomeDx assays have earned FDA Breakthrough Device Designation underscoring their clinical validity and potential for rapid regulatory pathways. Principal competitors in the market include Baylor Genetics Tempus through its Ambry Genetics subsidiary Variantyx Rady Children’s Hospital and various academic and commercial laboratories. While Illumina Inc. supplies sequencing equipment and reagents it also operates as a competitor in the broader genetic information space. GeneDx differentiates itself through its focus on rare disease depth its longitudinal patient data and its commitment to providing actionable reports that are accessible to non genetics clinicians.
GeneDx Holdings Corp. serves a varied customer base that includes hospitals academic medical centers specialty clinics and individual clinicians. Specific collaborators mentioned in the filing include Seattle Children’s Hospital and the University of Washington for the SeqFirst study and New York‑Presbyterian Columbia University New York State Department of Health and Illumina Inc. for the GUARDIAN study. The company’s primary payors are third party insurance companies managed care organizations and federal and state healthcare programs such as Medicare and Medicaid. Patients themselves also contribute revenue particularly for self pay or high deductible scenarios. Business to business clients consist of biopharma firms that utilize GeneDx’s data and information solutions for clinical trial recruitment target identification and real world evidence generation. Additionally the firm works with public health agencies and advocacy groups to advance newborn screening initiatives and to expand access to genomic testing in underserved populations. The customer base spans pediatric neurologists geneticists general pediatricians neonatologists and prenatal care providers reflecting the firm’s strategy to make exome and genome testing a frontline diagnostic tool across multiple care settings.
Sectors:Healthcare·TechnologySector rationaleThe company's primary revenue is generated from the sale of diagnostic test reports for exome and genome sequencing (ExomeDx and GenomeDx) delivered via CLIA-certified laboratories to hospitals and clinicians. A secondary sector of Technology is justified because the company sells independent data and information solutions, including access to the GeneDx Infinity dataset and cloud-based analysis services, to biopharma and research organizations.Industries:Diagnostic LabsDiagnostic LabsPrimaryGeneDx generates its primary revenue from the sale of diagnostic test reports for exome and genome sequencing, such as ExomeDx and GenomeDx. The company operates CLIA-certified high-complexity laboratories to provide these clinical laboratory and genetic testing services to hospitals, clinics, and clinicians.Healthcare ITHealthcare ITSecondaryThe company sells cloud-based analysis services and variant interpretation pipelines to biopharma and research organizations. These products are purpose-built for life sciences operations and genomic data analysis, fitting the definition of healthcare-specific IT platforms.Classified using BQ-MICSCIK: 0001818331
Bull & bear
Investment Thesis
▲ Bull case
The company reported first quarter revenues of $87,100,000 representing a 62% year over year increase in exome and genome sales and a 24% increase in test volumes for those flagship products. Average reimbursement rate for exome and genome rose to approximately $3,400 from $2,600 a year earlier reflecting improved payer adjudication and fewer denials. Management highlighted a disciplined approach to volume that prioritizes tests with high payment probability which supports sustainable revenue expansion. These trends suggest the core diagnostic business is scaling efficiently while maintaining profitability and generating cash for reinvestment.
The launch of the ultraRapid genome sequencing product with a 48 hour turnaround time provides a premium priced option for critically ill neonates in the NICU. Early feedback indicates strong reception due to speed and price point positioning the test as best in class for acute care settings. The company plans to drive adoption through health economic data that demonstrates cost savings for hospital systems when rapid results reduce length of stay and unnecessary procedures. Combined with the Epic Aura integration which streamlines order entry and result reporting the NICU is expected to become a meaningful contributor to volume in the second half of the year and beyond.
The pending acquisition of Fabric Genomics adds a software based interpretation as a service business that currently operates at near 70% gross margin and offers a recurring revenue stream complementary to the high margin testing business. Fabric’s cloud native platform enables GeneDx to serve international markets with tailored models that comply with local regulatory requirements while leveraging its centralized data asset for decentralized interpretation. Integration of Fabric’s AI capabilities with GeneDx’s existing data set is expected to lower cost per test and accelerate turnaround times creating a more scalable operation. The combined entity should generate platform economics that improve operating leverage and support margin expansion over the next two to three years.
Through the GUARDIAN study GeneDx has generated early evidence that up to 60% of babies in level IV NICU should receive a rapid genome test and that genomic newborn screening can identify disease in 3.2% of neonates who would otherwise remain undiagnosed for years. The company is sharing this knowledge with flagship programs across the country positioning itself as a strategic advisor to policymakers and state Medicaid programs. Legislative momentum is building with bills such as the Sunshine Genetics Act in Florida seeking to adopt whole genome newborn screening as a standard of care. Successful passage of similar legislation in additional states would create a durable demand pipeline that could materialize as a revenue contributor starting around 2027.
Beyond pediatrics GeneDx is actively pursuing adult indications such as immune deficiency disorders cerebral palsy and hearing loss to capture patients who remained undiagnosed in childhood and now present with symptoms later in life. The commercial team has added new call points including pediatric immunologists and is working to increase penetration among pediatric neurologists where market penetration already reached 14% in the first quarter. Expanding the test menu to cover more than 10,000 rare diseases allows the company to cross sell additional panels to existing clinicians and increase average revenue per account. These initiatives are expected to provide supplemental growth that complements the core pediatric neurology franchise and diversifies the revenue base.
The company reported first quarter revenues of $87,100,000 representing a 62% year over year increase in exome and genome sales and a 24% increase in test volumes for those flagship products. Average reimbursement rate for exome and genome rose to approximately $3,400 from $2,600 a year earlier reflecting improved payer adjudication and fewer denials. Management highlighted a disciplined approach to volume that prioritizes tests with high payment probability which supports sustainable revenue expansion. These trends suggest the core diagnostic business is scaling efficiently while maintaining profitability and generating cash for reinvestment.
The launch of the ultraRapid genome sequencing product with a 48 hour turnaround time provides a premium priced option for critically ill neonates in the NICU. Early feedback indicates strong reception due to speed and price point positioning the test as best in class for acute care settings. The company plans to drive adoption through health economic data that demonstrates cost savings for hospital systems when rapid results reduce length of stay and unnecessary procedures. Combined with the Epic Aura integration which streamlines order entry and result reporting the NICU is expected to become a meaningful contributor to volume in the second half of the year and beyond.
The pending acquisition of Fabric Genomics adds a software based interpretation as a service business that currently operates at near 70% gross margin and offers a recurring revenue stream complementary to the high margin testing business. Fabric’s cloud native platform enables GeneDx to serve international markets with tailored models that comply with local regulatory requirements while leveraging its centralized data asset for decentralized interpretation. Integration of Fabric’s AI capabilities with GeneDx’s existing data set is expected to lower cost per test and accelerate turnaround times creating a more scalable operation. The combined entity should generate platform economics that improve operating leverage and support margin expansion over the next two to three years.
Through the GUARDIAN study GeneDx has generated early evidence that up to 60% of babies in level IV NICU should receive a rapid genome test and that genomic newborn screening can identify disease in 3.2% of neonates who would otherwise remain undiagnosed for years. The company is sharing this knowledge with flagship programs across the country positioning itself as a strategic advisor to policymakers and state Medicaid programs. Legislative momentum is building with bills such as the Sunshine Genetics Act in Florida seeking to adopt whole genome newborn screening as a standard of care. Successful passage of similar legislation in additional states would create a durable demand pipeline that could materialize as a revenue contributor starting around 2027.
Beyond pediatrics GeneDx is actively pursuing adult indications such as immune deficiency disorders cerebral palsy and hearing loss to capture patients who remained undiagnosed in childhood and now present with symptoms later in life. The commercial team has added new call points including pediatric immunologists and is working to increase penetration among pediatric neurologists where market penetration already reached 14% in the first quarter. Expanding the test menu to cover more than 10,000 rare diseases allows the company to cross sell additional panels to existing clinicians and increase average revenue per account. These initiatives are expected to provide supplemental growth that complements the core pediatric neurology franchise and diversifies the revenue base.
Despite recent improvements in average reimbursement rate the company still collects payment on only about half of insurance adjudicated claims indicating a significant gap between billed and received amounts. The majority of denials remain administrative or procedural suggesting that payer policies and billing complexities continue to obstruct full reimbursement. Management acknowledged that the revenue cycle is not yet optimized and that achieving a payment rate closer to 80% will require sustained effort and payer engagement. Any slowdown in denial reduction or adverse changes in payer coverage could pressure the average reimbursement rate and offset volume gains.
The NICU opportunity remains largely untapped with fewer than 5% of babies currently receiving a genetic test and success hinges on multiple factors including UltraRapid acceptance Epic Aura integration and demonstrated health economic value. While the company has laid foundational infrastructure the conversion of pilots to sustained volume has historically been slower than anticipated in the diagnostics sector. If hospital administrators do not perceive sufficient clinical or economic benefit the NICU ramp may be delayed limiting the expected second half acceleration. Execution delays would also postpone the anticipated mix shift toward higher priced ultraRapid tests that could boost revenue per test.
The Fabric Genomics deal brings a software based business with a different cost structure and go to market model that requires successful integration of sales teams technology platforms and cultural alignment. Management noted that Fabric currently lacks meaningful commercial investment and its client base is undersized relative to its potential. Realizing the anticipated accretive effect on earnings in 2026 assumes that GeneDx can effectively cross sell its testing fabric services and achieve the projected revenue run rate. Integration challenges or slower than expected adoption of the interpretation as a service offering could diminish the expected margin benefits and add to operating expenses.
Launching new test indications such as immune deficiency disorders cerebral palsy and hearing loss requires changing entrenched prescribing behaviors among specialists who have historically relied on multi gene panels or chromosomal microarray. The commercial effort to educate physicians and secure reimbursement for these new indications is still early and there is limited visibility on uptake rates or payer acceptance. If reimbursement levels for these new tests trail those of the established exome and genome offerings the incremental volume may not translate into proportional revenue growth. Moreover the physician funnel for these indications is narrower than the pediatric neurologist base limiting the scalable upside.
The company’s exposure to Medicaid programs creates vulnerability to state level budget pressures or federal policy shifts that could reduce coverage for genomic testing. While management emphasized that children’s health is a bipartisan priority any changes to Medicaid reimbursement rates or eligibility criteria would directly impact the volume of tests billed to public payers. Additionally the broader diagnostic industry is facing scrutiny over utilization and cost containment which could lead to stricter prior authorization requirements. Such developments would increase administrative burden and could lower the effective reimbursement rate despite internal efforts to reduce denials.
Despite recent improvements in average reimbursement rate the company still collects payment on only about half of insurance adjudicated claims indicating a significant gap between billed and received amounts. The majority of denials remain administrative or procedural suggesting that payer policies and billing complexities continue to obstruct full reimbursement. Management acknowledged that the revenue cycle is not yet optimized and that achieving a payment rate closer to 80% will require sustained effort and payer engagement. Any slowdown in denial reduction or adverse changes in payer coverage could pressure the average reimbursement rate and offset volume gains.
The NICU opportunity remains largely untapped with fewer than 5% of babies currently receiving a genetic test and success hinges on multiple factors including UltraRapid acceptance Epic Aura integration and demonstrated health economic value. While the company has laid foundational infrastructure the conversion of pilots to sustained volume has historically been slower than anticipated in the diagnostics sector. If hospital administrators do not perceive sufficient clinical or economic benefit the NICU ramp may be delayed limiting the expected second half acceleration. Execution delays would also postpone the anticipated mix shift toward higher priced ultraRapid tests that could boost revenue per test.
The Fabric Genomics deal brings a software based business with a different cost structure and go to market model that requires successful integration of sales teams technology platforms and cultural alignment. Management noted that Fabric currently lacks meaningful commercial investment and its client base is undersized relative to its potential. Realizing the anticipated accretive effect on earnings in 2026 assumes that GeneDx can effectively cross sell its testing fabric services and achieve the projected revenue run rate. Integration challenges or slower than expected adoption of the interpretation as a service offering could diminish the expected margin benefits and add to operating expenses.
Launching new test indications such as immune deficiency disorders cerebral palsy and hearing loss requires changing entrenched prescribing behaviors among specialists who have historically relied on multi gene panels or chromosomal microarray. The commercial effort to educate physicians and secure reimbursement for these new indications is still early and there is limited visibility on uptake rates or payer acceptance. If reimbursement levels for these new tests trail those of the established exome and genome offerings the incremental volume may not translate into proportional revenue growth. Moreover the physician funnel for these indications is narrower than the pediatric neurologist base limiting the scalable upside.
The company’s exposure to Medicaid programs creates vulnerability to state level budget pressures or federal policy shifts that could reduce coverage for genomic testing. While management emphasized that children’s health is a bipartisan priority any changes to Medicaid reimbursement rates or eligibility criteria would directly impact the volume of tests billed to public payers. Additionally the broader diagnostic industry is facing scrutiny over utilization and cost containment which could lead to stricter prior authorization requirements. Such developments would increase administrative burden and could lower the effective reimbursement rate despite internal efforts to reduce denials.